Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin add-on to metformin in adults with type 2 diabetes mellitus
2010-024256-28Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Change in HbA1c from baseline to Week 18. Started Apr 2011; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-024256-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024256-28.